Alirocumab reduces dangerous coronary plaque and stabilizes high-risk lesions

The cold and flu aisles of pharmacies are bursting with options, though most share a relatively small roster of active ingredients in various combinations. MedPage

Ace­lyrin said a con­tract re­search or­ga­ni­za­tion con­duct­ing stud­ies of its lead ex­per­i­men­tal drug had made “clin­i­cal tri­al ex­e­cu­tion er­rors” and it was con­duct­ing an au­dit